Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Upcoming Luscii - an OMRON Healthcare service webinar: Enabling Exceptional At-home Care for Children
Date: 12 September 2024, 10:30 – 11.15am
They explore the opportunities of technology-enabled paediatric care.
Sign up here.
S-PRO has become a member of SwissICT, the largest professional association for the Information and Communications Technology industry in Switzerland. Read the full article here.
Attendees
Sponsors and
Exhibitors
Agenda
Webinars
Contact us